Mustapha Tehfé

7.8k total citations
90 papers, 1.1k citations indexed

About

Mustapha Tehfé is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Mustapha Tehfé has authored 90 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 52 papers in Pulmonary and Respiratory Medicine and 18 papers in Surgery. Recurrent topics in Mustapha Tehfé's work include Cancer Immunotherapy and Biomarkers (29 papers), Gastric Cancer Management and Outcomes (25 papers) and Lung Cancer Treatments and Mutations (22 papers). Mustapha Tehfé is often cited by papers focused on Cancer Immunotherapy and Biomarkers (29 papers), Gastric Cancer Management and Outcomes (25 papers) and Lung Cancer Treatments and Mutations (22 papers). Mustapha Tehfé collaborates with scholars based in Canada, United States and Germany. Mustapha Tehfé's co-authors include Normand Blais, Marie Florescu, Samer Tabchi, Jaffer A. Ajani, Kohei Shitara, Marcelo Garrido, Yelena Y. Janjigian, Kensei Yamaguchi, Tomasz Skoczylas and Denis Soulières and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Mustapha Tehfé

85 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mustapha Tehfé Canada 17 699 656 241 186 145 90 1.1k
Yu-Hong Li China 15 606 0.9× 392 0.6× 285 1.2× 110 0.6× 205 1.4× 19 922
Hironaga Satake Japan 18 667 1.0× 573 0.9× 372 1.5× 97 0.5× 156 1.1× 147 1.1k
Yen‐Yang Chen Taiwan 17 342 0.5× 241 0.4× 300 1.2× 169 0.9× 138 1.0× 70 785
Laura Visa Spain 15 662 0.9× 417 0.6× 262 1.1× 180 1.0× 334 2.3× 37 1.0k
Francesca Di Fabio Italy 18 791 1.1× 742 1.1× 421 1.7× 117 0.6× 79 0.5× 64 1.3k
Mariko Ogura Japan 15 694 1.0× 589 0.9× 254 1.1× 166 0.9× 167 1.2× 112 1.1k
Masato Ozaka Japan 21 1.2k 1.7× 581 0.9× 525 2.2× 188 1.0× 358 2.5× 186 1.5k
Wilson Luiz da Costa Brazil 14 403 0.6× 364 0.6× 291 1.2× 125 0.7× 74 0.5× 68 785
Isabel Sevilla Spain 19 951 1.4× 328 0.5× 161 0.7× 194 1.0× 179 1.2× 83 1.4k
Olivier Dubreuil France 15 932 1.3× 498 0.8× 378 1.6× 310 1.7× 382 2.6× 56 1.6k

Countries citing papers authored by Mustapha Tehfé

Since Specialization
Citations

This map shows the geographic impact of Mustapha Tehfé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mustapha Tehfé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mustapha Tehfé more than expected).

Fields of papers citing papers by Mustapha Tehfé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mustapha Tehfé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mustapha Tehfé. The network helps show where Mustapha Tehfé may publish in the future.

Co-authorship network of co-authors of Mustapha Tehfé

This figure shows the co-authorship network connecting the top 25 collaborators of Mustapha Tehfé. A scholar is included among the top collaborators of Mustapha Tehfé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mustapha Tehfé. Mustapha Tehfé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alameddine, Raafat, Marie Florescu, Mustapha Tehfé, et al.. (2025). Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study). Current Oncology. 32(2). 57–57. 1 indexed citations
2.
Chen, Eric X., Petr Kavan, Mustapha Tehfé, et al.. (2024). Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clinical Colorectal Cancer. 23(2). 183–193. 2 indexed citations
3.
Shitara, Kohei, Markus Moehler, Jaffer A. Ajani, et al.. (2024). Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.. Journal of Clinical Oncology. 42(16_suppl). 4040–4040. 3 indexed citations
4.
Snow, Stephanie, et al.. (2024). Best Practices for Managing Patients with Unresectable Metastatic Gastric and Gastroesophageal Junction Cancer in Canada. Current Oncology. 31(5). 2552–2565. 1 indexed citations
5.
Kim, Richard D., Mustapha Tehfé, Petr Kavan, et al.. (2024). Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clinical Colorectal Cancer. 23(2). 118–127.e6. 8 indexed citations
6.
Desîlets, Antoine, Wiam Belkaïd, Julie Malo, et al.. (2024). CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC. JTO Clinical and Research Reports. 5(12). 100737–100737. 2 indexed citations
7.
Gambaro, Karen, Maud Marques, Cyrla Hoffert, et al.. (2023). A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy. International Journal of Molecular Sciences. 25(1). 43–43.
8.
Wong, Philip, Laura Masucci, Marie Florescu, et al.. (2023). Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases. Neuro-Oncology Advances. 5(1). vdad018–vdad018. 11 indexed citations
9.
Tehfé, Mustapha, et al.. (2023). Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric Cancer. Current Oncology. 30(10). 9304–9316. 3 indexed citations
10.
Bahig, Houda, Normand Blais, Philip Wong, et al.. (2022). Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC). Clinical and Translational Radiation Oncology. 33. 115–119. 9 indexed citations
11.
12.
O’Kane, Grainne M., Sarah Picardo, Amy Zhang, et al.. (2020). Homologous recombination deficiency (HRD) scoring in pancreatic ductal adenocarcinoma (PDAC) and response to chemotherapy.. Journal of Clinical Oncology. 38(4_suppl). 741–741. 3 indexed citations
13.
Tehfé, Mustapha, Samer Tabchi, Maria Maddalena Laterza, & Ferdinando De Vita. (2018). Ramucirumab in Her-2-Positive Gastroesophageal Adenocarcinoma: An Argument for Overcoming Trastuzumab Resistance. Future Oncology. 14(3). 223–228. 6 indexed citations
14.
Juergens, Rosalyn A., Desirée Hao, Scott A. Laurie, et al.. (2017). MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226. Journal of Thoracic Oncology. 12(1). S392–S393. 11 indexed citations
15.
16.
Tabchi, Samer, Normand Blais, Marie‐Pierre Campeau, & Mustapha Tehfé. (2017). Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 79(2). 381–387. 8 indexed citations
17.
Ghosn, Marwan, Samer Tabchi, Hampig Raphaël Kourié, & Mustapha Tehfé. (2016). Metastatic gastric cancer treatment: Second line and beyond. World Journal of Gastroenterology. 22(11). 3069–3069. 27 indexed citations
18.
Tehfé, Mustapha, Scot Dowden, Hagen F. Kennecke, et al.. (2016). nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Advances in Therapy. 33(5). 747–759. 16 indexed citations
19.
Tehfé, Mustapha, Marie Florescu, Denis Soulières, et al.. (2015). Phase I and II studies of the decitabine–genistein drug combination in advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). e13556–e13556. 7 indexed citations
20.
Fuchs, Charles S., Josep Tabernero, Jiří Tomášek, et al.. (2015). Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).. Journal of Clinical Oncology. 33(15_suppl). 4029–4029. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yu-Hong Li Breakdown of academic impact, for papers by Hironaga Satake Breakdown of academic impact, for papers by Yen‐Yang Chen Breakdown of academic impact, for papers by Laura Visa Breakdown of academic impact, for papers by Francesca Di Fabio Breakdown of academic impact, for papers by Mariko Ogura Breakdown of academic impact, for papers by Masato Ozaka Breakdown of academic impact, for papers by Wilson Luiz da Costa Breakdown of academic impact, for papers by Isabel Sevilla Breakdown of academic impact, for papers by Olivier Dubreuil
Rankless by CCL
2026